These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37953806)

  • 1. Cerebrospinal fluid biomarkers profile in scans without evidence of dopaminergic deficits (SWEDD).
    Nabizadeh F; KamaliZonouzi S; Noori M
    IBRO Neurosci Rep; 2023 Dec; 15():320-326. PubMed ID: 37953806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson's disease: a cross-sectional and longitudinal study.
    Nabizadeh F; Pirahesh K; Valizadeh P
    J Neurol; 2022 Sep; 269(9):4836-4845. PubMed ID: 35426534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson's disease.
    Nabizadeh F; Pirahesh K; Ramezannezhad E
    Neurol Sci; 2023 Feb; 44(2):573-585. PubMed ID: 36227385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in tremor-dominant Parkinson's disease.
    Nabizadeh F; Sodeifian F; Kargar A
    Acta Neurol Belg; 2023 Aug; 123(4):1429-1437. PubMed ID: 37000407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of autonomic symptoms with cerebrospinal fluid biomarkers in Parkinson disease and scans without evidence of dopaminergic deficit.
    Yu Z; Li Y;
    Medicine (Baltimore); 2021 Feb; 100(7):e24837. PubMed ID: 33607852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
    Kang JH; Mollenhauer B; Coffey CS; Toledo JB; Weintraub D; Galasko DR; Irwin DJ; Van Deerlin V; Chen-Plotkin AS; Caspell-Garcia C; Waligórska T; Taylor P; Shah N; Pan S; Zero P; Frasier M; Marek K; Kieburtz K; Jennings D; Tanner CM; Simuni T; Singleton A; Toga AW; Chowdhury S; Trojanowski JQ; Shaw LM;
    Acta Neuropathol; 2016 Jun; 131(6):935-49. PubMed ID: 27021906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
    Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
    JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The associations of cerebrospinal fluid biomarkers with cognition, and rapid eye movement sleep behavior disorder in early Parkinson's disease.
    Tao M; Dou K; Xie Y; Hou B; Xie A
    Front Neurosci; 2022; 16():1049118. PubMed ID: 36507360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease.
    Dolatshahi M; Pourmirbabaei S; Kamalian A; Ashraf-Ganjouei A; Yaseri M; Aarabi MH
    Front Neurol; 2018; 9():560. PubMed ID: 30050494
    [No Abstract]   [Full Text] [Related]  

  • 10. CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.
    Gao R; Zhang G; Chen X; Yang A; Smith G; Wong DF; Zhou Y
    PLoS One; 2016; 11(10):e0164762. PubMed ID: 27764160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.
    Marek K; Chowdhury S; Siderowf A; Lasch S; Coffey CS; Caspell-Garcia C; Simuni T; Jennings D; Tanner CM; Trojanowski JQ; Shaw LM; Seibyl J; Schuff N; Singleton A; Kieburtz K; Toga AW; Mollenhauer B; Galasko D; Chahine LM; Weintraub D; Foroud T; Tosun-Turgut D; Poston K; Arnedo V; Frasier M; Sherer T;
    Ann Clin Transl Neurol; 2018 Dec; 5(12):1460-1477. PubMed ID: 30564614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease.
    Parnetti L; Farotti L; Eusebi P; Chiasserini D; De Carlo C; Giannandrea D; Salvadori N; Lisetti V; Tambasco N; Rossi A; Majbour NK; El-Agnaf O; Calabresi P
    Front Aging Neurosci; 2014; 6():53. PubMed ID: 24744728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease.
    Irwin DJ; Fedler J; Coffey CS; Caspell-Garcia C; Kang JH; Simuni T; Foroud T; Toga AW; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Weintraub D; Mollenhauer B; Galasko DR; Siderowf A; Marek K; Trojanowski JQ; Shaw LM;
    Ann Neurol; 2020 Sep; 88(3):574-587. PubMed ID: 32542885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with scans without evidence of dopaminergic deficit (SWEDD) do not have early Parkinson's disease: Analysis of the PPMI data.
    Lee JW; Song YS; Kim H; Ku BD; Lee WW
    PLoS One; 2021; 16(2):e0246881. PubMed ID: 33566871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.
    Mollenhauer B; Caspell-Garcia CJ; Coffey CS; Taylor P; Shaw LM; Trojanowski JQ; Singleton A; Frasier M; Marek K; Galasko D;
    Neurology; 2017 Nov; 89(19):1959-1969. PubMed ID: 29030452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease.
    Toledo JB; Korff A; Shaw LM; Trojanowski JQ; Zhang J
    Acta Neuropathol; 2013 Nov; 126(5):683-97. PubMed ID: 23812319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preserved Extrastriatal
    Nicastro N; Burkhard PR; Garibotto V
    Mol Imaging Biol; 2020 Dec; 22(6):1592-1599. PubMed ID: 32468408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease.
    Murakami H; Tokuda T; El-Agnaf OMA; Ohmichi T; Miki A; Ohashi H; Owan Y; Saito Y; Yano S; Tsukie T; Ikeuchi T; Ono K
    BMC Neurol; 2019 Jun; 19(1):113. PubMed ID: 31164098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal trajectory of biofluid markers in Parkinson's disease.
    Baek MS; Lee MJ; Kim HK; Lyoo CH
    Sci Rep; 2021 Jul; 11(1):14820. PubMed ID: 34285331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.